OKYO Pharma (OKYO) Chief Development Officer reports stock and option holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
OKYO Pharma Ltd Chief Development Officer Gary S. Jacob filed an initial ownership report showing he holds 108,920 shares of common stock directly. He also reports multiple option awards over common stock with exercise prices ranging from 1.46 to 2.75 per share and expirations between 2033 and 2035.
Positive
- None.
Negative
- None.
Insider Trade Summary
19 transactions reported
Mixed
19 txns
Insider
JACOB GARY S
Role
Chief Development Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | COMMON STOCK | -- | -- | -- |
Holdings After Transaction:
Options — 21,154 shares (Direct);
COMMON STOCK — 108,920 shares (Direct)
Footnotes (1)
FAQ
What does the OKYO Pharma (OKYO) Form 3 filed by Gary S. Jacob show?
The Form 3 shows Gary S. Jacob, Chief Development Officer of OKYO Pharma, reporting initial beneficial ownership. He directly holds 108,920 common shares and multiple option positions over common stock at various exercise prices and expirations through 2035.
Does the OKYO Pharma (OKYO) Form 3 show any recent insider buying or selling?
The Form 3 lists holdings only and shows no reported insider purchases or sales. Transactions are classified as holdings with unknown transaction codes and a neutral net buy/sell direction in the transaction summary.
What role does Gary S. Jacob hold at OKYO Pharma in this Form 3?
In this Form 3, Gary S. Jacob is identified as both a director and an officer of OKYO Pharma, serving as Chief Development Officer, and he reports his direct holdings of common stock and options over common stock.